PMID- 33214069
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Linking)
VI  - 27
IP  - 4
DP  - 2021 Apr
TI  - Successful bridge therapy of gilteritinib to cord blood transplantation in 
      relapsed acute myeloid leukemia after bone marrow transplantation.
PG  - 639-641
LID - S1341-321X(20)30410-4 [pii]
LID - 10.1016/j.jiac.2020.11.003 [doi]
AB  - The FMS-related tyrosine kinase 3 (FLT3) internal tandem duplication mutations 
      (FLT3-ITD) positive acute myeloid leukemia (AML) is a disease with a dismal 
      outcome. Gilteritinib is a second-generation FLT3 inhibitor with activity against 
      ITD and high affinity toward the FLT3 receptor, thereby showing therapeutic 
      potential for relapsed/refractory FLT3-mutated AML. Bone marrow transplantation 
      (BMT) from a human leukocyte antigen (HLA) identical sibling donor was performed 
      in a 38-year-old Japanese male with FLT3-ITD positive AML. Neutrophil engraftment 
      (>0.5 x 10(9)/L) was achieved on day 16, and bone marrow remission was revealed 
      on day 32. The patient's AML relapsed hematologically four months after BMT and 
      was resistant to salvage chemotherapy. Gilteritinib was administered and the 
      patient achieved non-remission but 'stable disease' status according to the 
      response criteria. During administration, liver damage was observed but 
      controllable. The patient received cord blood transplantation (CBT) as the second 
      hematopoietic stem cell transplantation (HSCT) three months after relapse and 
      achieved second remission. There was no evidence of recurrence of AML four months 
      after CBT. This case demonstrates that gilteritinib can control FLT3-ITD positive 
      AML that relapsed early after initial HSCT and can bridge to second HSCT.
CI  - Copyright (c) 2020 Japanese Society of Chemotherapy and The Japanese Association 
      for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Kamitani, Iku
AU  - Kamitani I
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Saito, Takeshi
AU  - Saito T
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan. Electronic address: 
      takexsaito@jikei.ac.jp.
FAU - Yokoyama, Hiroki
AU  - Yokoyama H
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Nakano, Aya
AU  - Nakano A
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Ishii, Hiroto
AU  - Ishii H
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Tanoue, Susumu
AU  - Tanoue S
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Hattori, Daiki
AU  - Hattori D
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Oshima, Sayaka
AU  - Oshima S
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Ishii, Shoko
AU  - Ishii S
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Gunji, Tadahiro
AU  - Gunji T
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Fukushima, Ryoko
AU  - Fukushima R
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Katsube, Atsushi
AU  - Katsube A
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Shimada, Takaki
AU  - Shimada T
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
FAU - Nishiwaki, Kaichi
AU  - Nishiwaki K
AD  - Division of Clinical Oncology/Hematology, The Jikei University Kashiwa Hospital, 
      Japan.
FAU - Dobashi, Nobuaki
AU  - Dobashi N
AD  - Division of Clinical Oncology/Hematology, The Jikei University Daisan Hospital, 
      Japan.
FAU - Yano, Shingo
AU  - Yano S
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Japan.
LA  - eng
PT  - Case Reports
DEP - 20201117
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - 0 (Aniline Compounds)
RN  - 0 (Pyrazines)
RN  - 0 (gilteritinib)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
SB  - IM
MH  - Adult
MH  - Aniline Compounds
MH  - Bone Marrow Transplantation
MH  - *Cord Blood Stem Cell Transplantation
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Leukemia, Myeloid, Acute/drug therapy
MH  - Male
MH  - Mutation
MH  - Pyrazines
MH  - fms-Like Tyrosine Kinase 3/genetics
OTO - NOTNLM
OT  - FLT3-ITD
OT  - Giltertinib
OT  - Transplantation
COIS- Declaration of competing interest All authors declare that they have no conflict 
      of interest.
EDAT- 2020/11/21 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/11/20 05:36
PHST- 2020/09/21 00:00 [received]
PHST- 2020/10/20 00:00 [revised]
PHST- 2020/11/03 00:00 [accepted]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/11/20 05:36 [entrez]
AID - S1341-321X(20)30410-4 [pii]
AID - 10.1016/j.jiac.2020.11.003 [doi]
PST - ppublish
SO  - J Infect Chemother. 2021 Apr;27(4):639-641. doi: 10.1016/j.jiac.2020.11.003. Epub 
      2020 Nov 17.